when will i start losing weight on tirzepatide vs. Semaglutide: Which Loss Medication Is Right for You? Tirzepatide for Medical Weight Loss

Lillys GLP-1 revenue surged from $7.6B to $40.7B between 2022 and 2025, a steeper ramp than Novo Nordisks $12.3B-to-$35.0B climb over the same period, and the gap is widening: Lilly is guiding for continued growth in 2026 while Novo projects a 5% to 13% decline in adjusted sales

Unleash the Beast We support the scene, our bands, our athletes and our fans

Our data suggest that individuals with higher levels of GGT could be considered as having an increased risk of developing SSc

DexCom (NasdaqGS:DXCM) is seeing higher adoption of its continuous glucose monitoring systems among patients using GLP-1 drugs, as physicians pair both therapies for diabetes care

Beyond 12 months: sustained metabolic adaptation, stabilization of weight, and cardiovascular benefits